title: Clopidogrel: to test or not to test? That is the question--still.
authors.affiliation: Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. cpcannon@partners.org
authors.forename: Christopher P
authors.initials: CP
authors.lastname: Cannon
mesh_terms: D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics* / Q000378:metabolism; D001792:Blood Platelets / Q000187:drug effects* / Q000502:physiology; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000235:genetics; D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19; D005820:Genetic Testing / Q000706:statistics & numerical data; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010979:Platelet Function Tests / Q000706:statistics & numerical data; D011110:Polymorphism, Genetic; D057285:Precision Medicine; D013988:Ticlopidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D013988:Ticlopidine